Yibin Guo, Jiang Zheng, Hong Zhou, Gengfa Lv, Liangxi Wang, Guo Wei, Yongling Lu
Medical Research Center, Southwest Hospital, Third Military Medical University, Chongqing 400038, PR China.
Biochem Pharmacol. 2005 Jul 15;70(2):209-19. doi: 10.1016/j.bcp.2005.04.040.
Sepsis is a complex clinical syndrome that results from a harmful host response to infection, in which foreign bacteria and lipopolysaccharide (LPS) are potent activators of different immune cells, including monocytes and macrophages. To date, there are currently few effective adjuvant therapies in clinical use except activated protein C focusing on the coagulation system. Mastoparans (MPs) are wasp venom cationic amphiphilic tetradecapeptides; these are capable of modulating various cellular activities, including stimulation of GTP-binding protein, phospholipase C and can bind to a phospholipid bilayer. Masroparan-1 (MP-1, INLKAIAALAKKLL-NH2), a tetradecapeptide toxin isolated from hornet venom, was synthesized chemically. In this study, Escherichia coli 25922 (E. coli 25922) and LPS were used to induce sepsis in an animal model. We found that MP-1 treatment at 3 mg/kg protected mice from otherwise lethal bacteria and LPS challenges. MP-1 has antibacterial capabilities against Gram-negative and Gram-positive bacteria. Its antibacterial action against E. coli may result from the destruction of bacterial membrane structures. In addition, treatment of murine peritoneal macrophages with MP-1 potently inhibited the respiratory burst. This effect maybe related to an inhibition of NADPH oxidase in the membrane. Furthermore, MP-1, bound with high-affinity to LPS and lipid A with dissociation equilibrium constants of 484 and 456 nM, respectively, and neutralized LPS in a dose-dependent manner. MP-1 also significantly reduced the expression of TLR4, TNF-alpha and IL-6 mRNA and the release of cytokines in LPS-stimulated murine peritoneal macrophages. Our results shows that the MP-1-mediated protection of mice from lethal challenge by live bacteria and LPS was associated with its bactericidal action and inhibition of inflammatory responses by macrophages to both bacteria and LPS (the release of cytokines and reactive oxygen species).
脓毒症是一种复杂的临床综合征,由宿主对感染的有害反应引起,其中外来细菌和脂多糖(LPS)是包括单核细胞和巨噬细胞在内的不同免疫细胞的强效激活剂。迄今为止,除了专注于凝血系统的活化蛋白C外,临床应用中几乎没有有效的辅助治疗方法。蜂毒肽(MPs)是黄蜂毒液中的阳离子两亲性十四肽;它们能够调节各种细胞活动,包括刺激GTP结合蛋白、磷脂酶C,并且可以与磷脂双层结合。从黄蜂毒液中分离出的十四肽毒素蜂毒肽-1(MP-1,INLKAIAALAKKLL-NH2)通过化学合成得到。在本研究中,使用大肠杆菌25922(E. coli 25922)和LPS在动物模型中诱导脓毒症。我们发现,以3 mg/kg的剂量用MP-1治疗可保护小鼠免受致死性细菌和LPS攻击。MP-1对革兰氏阴性菌和革兰氏阳性菌均具有抗菌能力。其对大肠杆菌的抗菌作用可能源于细菌膜结构的破坏。此外,用MP-1处理小鼠腹腔巨噬细胞可有效抑制呼吸爆发。这种作用可能与膜中NADPH氧化酶的抑制有关。此外,MP-1与LPS和脂质A具有高亲和力结合,解离平衡常数分别为484和456 nM,并以剂量依赖方式中和LPS。MP-1还显著降低了LPS刺激的小鼠腹腔巨噬细胞中TLR4、TNF-α和IL-6 mRNA的表达以及细胞因子的释放。我们的结果表明,MP-1介导的保护小鼠免受活细菌和LPS致死性攻击的作用与其杀菌作用以及抑制巨噬细胞对细菌和LPS的炎症反应(细胞因子和活性氧的释放)有关。